A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms ( SNPs ) and greater improvement in visual acuity ( VA ) to treatment with ranibizumab , an anti-vascular endothelial growth factor ( VEGF ) drug , in patients with neovascular age-related macular degeneration ( AMD ) .